Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000984 | 0.77 | SIGMAR1 (0.44) | SIGMAR1EBPPDK1SMN1; SMN2KDM4E | |
| SCHEMBL10815846 | 0.77 | SIGMAR1 (0.44) | SIGMAR1EBPPDK1SMN1; SMN2KDM4E | |
| SCHEMBL1072148 | 0.77 | SIGMAR1 (0.44) | SIGMAR1EBPPDK1SMN1; SMN2KDM4E | |
| SCHEMBL4745932 | 0.77 | SIGMAR1 (0.44) | SIGMAR1EBPPDK1SMN1; SMN2KDM4E | |
| SCHEMBL4317035 | 0.74 | MAPK8 (0.39) | SIGMAR1EBPPDK1SMN1; SMN2KDM4E | |
| SCHEMBL14067375 | 0.73 | SIGMAR1 (0.48) | SIGMAR1EBPPDK1SMN1; SMN2KDM4E | |
| SCHEMBL12125047 | 0.70 | SIGMAR1 (0.56) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL11962148 | 0.70 | SIGMAR1 (0.56) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL4550370 | 0.70 | SIGMAR1 (0.56) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL12125120 | 0.70 | SIGMAR1 (0.56) | SIGMAR1EBPPDK1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| EP-3489238-A1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | Dart NeuroScience (Cayman) Ltd (KY) | 2019-05-29 | — | — | EP | claimed |
| EP-2861605-B1 | 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2017-05-03 | — | — | EP | claimed |
| US-9499562-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-11-22 | — | — | US | claimed |
| US-9284335-B2 | Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-03-15 | — | — | US | claimed |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2016-02-04 | — | — | US | claimed |
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-06-11 | — | — | US | claimed |
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | disclosed |
| EP-3489238-A1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | Dart NeuroScience (Cayman) Ltd (KY) | 2019-05-29 | — | — | EP | disclosed |
| EP-2861603-B1 | 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-19 | — | — | EP | disclosed |
| US-10092575-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-10-09 | — | — | US | disclosed |
| US-20170209459-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-27 | — | — | US | disclosed |
| EP-2861605-B1 | 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2017-05-03 | — | — | EP | disclosed |
| US-9499562-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-11-22 | — | — | US | disclosed |
| US-9284335-B2 | Substituted pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidines, pyrido[2,3-e][1,2,4]triazolo[1,5-c]pyrimidines and/or [1,2,4]triazolo[1,5-c]pteridines for treatment of central nervous system diseases and disorders | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2016-03-15 | — | — | US | disclosed |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2016-02-04 | — | — | US | disclosed |
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092575-B2 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds | TPMT, PSEN2, GRIN2C | SIGMAR1 2893/4885EBP 3080/4885PDK1 2348/4885 |
| US-20150158885-A1 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | MAPT, PYGB, PSEN2 | SIGMAR1 3207/4885EBP 3313/4885PDK1 1094/4885 |
| US-20160031901-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | TPMT, PSEN2, GRIN2C | SIGMAR1 2800/4885EBP 2514/4885PDK1 2270/4885 |
| US-20170209459-A1 | SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS | TPMT, PSEN2, GRIN2C | SIGMAR1 2893/4885EBP 3080/4885PDK1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.